EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jul 11, 2025
Trial Information
Current as of July 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving how doctors find and understand heart problems caused by inflammation linked to autoimmune and inflammatory diseases. These conditions can affect the heart in different ways and may increase the risk of serious heart issues. The study will use advanced heart imaging tests, like MRI scans and special PET scans, to see how common heart involvement is in people who have or are suspected to have these inflammatory heart conditions. The goal is to better detect heart problems early and learn more about how these diseases affect the heart over time.
People who are 18 years or older and have been referred for heart imaging because doctors suspect they might have one of several inflammatory heart conditions—such as myocarditis (heart muscle inflammation), pericarditis (inflammation of the heart lining), or heart problems related to diseases like lupus, rheumatoid arthritis, or vasculitis—may be eligible to join. Participants will undergo one or more heart imaging tests as part of their usual care, and the study will collect information from these exams to help improve diagnosis and care for future patients. This study is currently not recruiting yet, but it welcomes adults of all genders who fit the criteria and are able to agree to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 years
- • 2. Ability to provide informed non-opposition
- • 3. Referred for a CMR and/or nuclear imaging exam
- AND a suspicion of one of the following ICARDs :
- • 1. Suspected Myocarditis (acute or chronic, and whatever the aetiologies)
- • 2. Suspected Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA)
- • 3. Suspected Tako-Tsubo
- • 4. Suspected Pericarditis (acute or chronic, and whatever the aetiologies)
- 5. Suspected Connective tissue disease with cardiovascular involvement:
- • Systemic sclerosis
- • Systemic lupus erythematosus
- • Antiphospholipid syndrome
- • Idiopathic inflammatory myopathies
- • Rheumatoid arthritis, spondylarthritis
- 6. Suspected Vasculitis with cardiovascular involvement:
- • Small-vessel vasculitis (ANCA...)
- • Large vessel vasculitis (Behcet disease, Takayasu...)
- 7. Suspected Inflammatory disease with cardiovascular involvement:
- • Sarcoidosis
- • Still disease
- Exclusion Criteria:
- • 1. Inability to provide non-opposition
- • 2. History of heart transplant
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported